Abstract
We investigated the effects of ketoconazole on the oral bioavailability of morpholine-urea-phenylalanine-homophenylalanine-vinylsulfone-phenyl (K02), a vinylsulfone peptidomimetic cysteine protease inhibitor, and a P450 3A (CYP3A) and P-glycoprotein dual substrate, in male Sprague-Dawley rats, so as to evaluate the roles of CYP3A and P-gp in K02 disposition. Male Sprague-Dawley rats (8–10 wk old,n = 3–6) were administered a single dose of K02 (10 mg/kg) i.v. or (30 mg/kg) p.o. with or without a concomitant oral dose of ketoconazole (20 mg/kg). Blood samples were collected from 2 min to 8 h after administration through a implanted jugular vein cannula. K02 plasma concentrations were determined by liquid chromatography/mass spectrometer/mass spectrometer analysis. Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 ± 4.4 to 102 ± 24 mg · min/liter and decreased K02 oral plasma clearance from 3810 ± 1620 to 306 ± 60 ml/min/kg. With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 ± 17 to 107 ± 14 mg · min/liter) and clearance (from 110 ± 22 to 95 ± 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 ± 1.4 to 31.0 ± 7.5% (P < .001). In summary, ketoconazole, a dual inhibitor of CYP3A and P-glycoprotein, can effectively increase K02 oral bioavailability by inhibiting the CYP3A/P-gp absorption barrier in the small intestine.
Footnotes
-
Send reprint requests to: Dr. Leslie Z. Benet, Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco, CA 94143-0446.
-
↵1 This work was supported by National Institutes of Health Grant CA 72006.
- Abbreviations:
- K02
- morpholine-urea-phenylalanine-homophenylalanine-vinylsulfone-phenyl
- CYP
- cytochrome P450
- P-gp
- P-glycoprotein
- MDR
- multidrug resistance
- ABC
- ATP-binding cassette
- IC50
- 50% inhibitory concentration
- MDCK
- Madin-Darby canine kidney cells
- AUC
- area under curve
- CL
- clearance
- F
- oral drug bioavailability
- MAT
- mean absorption time
- MRT
- mean resident time
- Tmax
- peak time
- Vss
- volume of distribution at steady state
- HPLC
- high-performance liquid chromatography
- Received January 6, 1998.
- Accepted May 16, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|